Cancer was once considered incurable in Japan. But the latest statistics reveal a dramatic range: prostate cancer has a 94.3% five-year survival rate, while pancreatic cancer remains at just 10%. Japan's first nationwide cancer registry data shows survival rates ranging from around 10% to over 90% depending on the type, a stark reminder of both medical progress and ongoing challenges.

Japan's First Comprehensive National Cancer Registry Data

In November 2025, Japan's National Cancer Center released groundbreaking data on cancer survival rates. The study analyzed approximately 2.54 million patients diagnosed between 2012 and 2015, calculating "net survival rates" that isolate cancer as the sole cause of death.

This statistical milestone marks the first large-scale aggregation covering the entire nation following Japan's transition from regional to national cancer registration. The data comes from 44 prefectures meeting international quality standards, enabling meaningful global comparisons.

Significant Disparities by Cancer Type

High Survival Group (70-100%)

For men, prostate cancer leads at 94.3%, followed by skin cancer (90.9%) and thyroid cancer (88.6%). Among women, thyroid cancer tops the list at 92.7%, with skin cancer (92.4%) and breast cancer (88.7%) following closely.

These cancers share common characteristics: relatively slow progression and detectability through regular screening programs.

Medium Survival Group (30-69%)

Stomach cancer (63.5%) and colorectal cancer (67.2%), both prevalent among Japanese, fall into this middle range. Lung cancer (35.5%) and liver cancer (33.7%) also appear here, though early detection significantly improves outcomes for these types.

Low Survival Group (0-29%)

Pancreatic cancer presents the most challenging prognosis, with survival rates of just 10.7% for men and 10.2% for women. Gallbladder and bile duct cancers remain similarly difficult to treat effectively.

The Dramatic Impact of Early Detection

Perhaps the most striking finding is how survival rates vary dramatically by stage of diagnosis.

For stomach cancer, patients diagnosed while the cancer remains localized show a 92.4% survival rate. However, when distant metastasis is present, this plummets to 6.3%.

Colorectal cancer follows a similar pattern: 92.3% for localized versus 16.8% with distant spread. Female breast cancer demonstrates this even more starkly: 98.4% for early-stage versus 38.5% with metastasis.

Three Decades of Progress

Analyzing trends from 1993 to 2015 reveals encouraging improvements across many cancer types.

Notable improvements for men:

  • Prostate cancer: +34.9 percentage points
  • Multiple myeloma: +21.0 percentage points
  • Malignant lymphoma: +18.2 percentage points

Notable improvements for women:

  • Malignant lymphoma: +21.6 percentage points
  • Leukemia: +19.5 percentage points
  • Lung cancer: +18.4 percentage points

These gains reflect advances in targeted therapies, immunotherapy, diagnostic technology, and expanded screening programs.

Persistent Challenges

Not all cancers have improved. Bladder cancer survival rates actually declined for both sexes (men: -10.6 points, women: -5.9 points). Cervical cancer in women also dropped by 1.3 points, suggesting issues with prevention and screening efforts.

Pancreatic and gallbladder/bile duct cancers showed minimal improvement over the 30-year period, highlighting urgent needs for therapeutic breakthroughs.

Age-Related Variations

For most cancers, survival rates decrease with age, likely due to comorbidities and limitations on aggressive treatment in elderly patients.

Prostate cancer is a notable exception, where younger patients actually show lower survival rates. This may reflect that early-onset prostate cancer tends to be more aggressive forms of the disease.

Japan's Position in Global Cancer Care

Japan has achieved remarkable success in reducing mortality from stomach and liver cancers through widespread H. pylori eradication and hepatitis virus control programs.

However, international comparisons suggest Japan lags in reducing deaths from "screening-detectable cancers" like colorectal, breast, and cervical cancers. Increasing screening participation rates remains a key challenge.

What About Your Country?

In Japan, discussions continue about improving cancer screening rates and expanding insurance coverage for new treatments. While the importance of early detection is clear, debates persist about cost-effectiveness and resource allocation.

How widespread is cancer screening in your country? What access do patients have to the latest treatments? How does your society discuss "living with cancer"? We'd love to hear your perspectives on cancer care in your part of the world.

References